SIMAP

SIMAP will develop a simulation model of the cancer related MAP-kinase pathway, integrating and analyzing data from various types of resources, which may assist in the development of better cancer treatment.

The completion of the human genome gave hope for a new age of medical understanding, but 4-5 years later costs of drug development are still rising and the success rate has not improved. Drugs that have already hit the market are found to have major side effects not perceived in the past and are often given to patients without discrimination on their likeliness to respond.

Large scale methodologies that thrive in recent years, allowed the industry and academia to gather more information on RNAs and proteins. However, the understanding of the molecular and cellular processes is still lacking, not to mention the connection to the clinical outcome. In order to fully use this data, a comprehensive integration and modelling effort is needed. A systematic rational hypothesis-driven research approach connecting all those levels of information is a much needed computational tool. This is the main goal of SIMAP project.

The ultimate goal of SIMAP is to develop a comprehensive simulation biochemical model of EGFRMAP kinase pathway in connection to cancer clinical information. SIMAP will:

  • Incorporate low-level biochemical modelling of individual molecules;
  • Simulate the behaviour of the pathway;
  • Add genomic and proteomic data;
  • Incorporate individual patients’ responses; and
  • Analyze sub population of responses in the context of the biochemical behaviour and genotype data

For further information, please visit:
http://www.simap-project.org

Project co-ordinator:
Compugen Ltd.

Partners:

  • Aureus Pharma, (FR)
  • Compugen Ltd., (IL)
  • Consejo Superior de Investigaciones Científicas, (ES)
  • Halevi Dweck & Co.Arttic Israel Company Ltd., (IL)
  • Fundacio Institut De Recerca De L'Hospital Universitari Vall D'Hebron, (ES)
  • Fondazione IRCCS Istituto Nazionale Dei Tumori, (IT)
  • The Max-Planck Institute for Infection Biology, (DE)
  • The University of Glasgow, (UK)
  • The Weizmann Institute of Science, (IL)

Timetable: from 01/06 – to 12/08

Total cost: € 4.464.201

EC funding: € 3.126.662

Instrument: STREP

Project Identifier: IST-2004-027265

Source: FP6 eHealth Portfolio of Projects

Most Popular Now

MRI Predict Intelligence Levels in Child…

A group of researchers from the Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE) took 4th place in the international MRI-based adolescent intelligence prediction competition. For the first...

CAD4TB: Artificial Iintelligence for Tub…

Is it possible to screen thousands of people for tuberculosis using artificial intelligence in a country where internet barely exists? It is with CAD4TB. As of October, this innovative software...

Pros and Cons of Mommy Mobile Apps

Mobile phone apps are increasingly being used to support breastfeeding decisions - sometimes at a cost, a Flinders University study indicates. The objective approach of most infant feeding (IF) apps...

Finally, Machine Learning Interprets Gen…

In this age of "big data," artificial intelligence (AI) has become a valuable ally for scientists. Machine learning algorithms, for instance, are helping biologists make sense of the dizzying number...

Philips Expands its Range of Consumer-Fo…

At CES 2020, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its expansion of personalized consumer health solutions that help shape the industry of...

Gloucestershire Hospitals Announce Signi…

Gloucestershire Hospitals NHS Foundation Trust has gone live with the first elements of its Allscripts Sunrise electronic patient record just five months after signing a contract with the company. The trust...

Bayer and Exscientia Collaborate to Leve…

Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia's proprietary...

A Better Testing Method for Patients wit…

Parkinson's disease is a neurodegenerative disorder that manifests through symptoms such as tremor, slow movements, limb rigidity and gait and balance problems. As such, nearly all diagnostic testing revolves around...

Artificial Intelligence (AI) can Detect …

A new technology for detecting low glucose levels via ECG using a non-invasive wearable sensor, which with the latest Artificial Intelligence can detect hypoglycaemic events from raw ECG signals has...